Transaction · 0001817199-26-000008

Ring Christine

Ring Christine, CLO, reported a transaction classified as grant at Nurix Therapeutics, Inc. involving 93750.000000 shares for an estimated $0.00. Reported holdings after the transaction were 93750.000000 shares. A 10b5-1 reference was not detected in the stored filing text.

grantSEC transaction code ACLO
NRIXNurix Therapeutics, Inc.
Filing timeFeb 10
Trade dateFeb 10, 2026
Filing · SECView on SEC
InsiderProfile

Price performance since filing

Close on the filing date, the pre-filing context, and the forward return at standard windows
Price at filing
$16.45
Pre-filing
1mo ago +17.3%1w ago +2.1%1d ago +1.6%
Returns since
7d -4.9%30d -5.1%90d -1.0%180d +55.2%1y +65.5%

NRIX price since this filing

30 days of pre-filing context and vertical markers at the filing date plus 7d / 30d / 90d / 180d / 1y afterwards
NRIX since 2026-02-10Filed 205 days ago · 30 days of pre-filing context shaded
Loading…
Filing datePost-filing windows (7d, 30d, 90d, 180d, 1y)30 days of pre-filing context

Transaction facts

Stored Form 4 columns with their raw values

Derivative
Type
grant
Code A
Identifier
0001817199-26-000008
Employee Stock Option (right to buy)
Transaction date
Feb 10, 2026
Filed Feb 10, 2026, 10:55 PM · 0d delay
Shares
93.7k sh
$0 per share
Estimated value
$0
Computed from shares × price
Holdings after
93.7k sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $10.0MLarge $100M
Derivative Transaction Direct Ownership Large Holdings Increase
-6score
Filing-only score

-6

Compact filing score computed from stored Form 4 facts. Version v1.

Mixed or weak signal

This filing has a negative filing-only score. It may be less informative as an insider-activity signal and needs extra context.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

Chief Legal Officer

Officer YesDirector No10% NoOther No
Footnotes & amended
  1. F1

    The stock option vests as to 1/36 of the total shares monthly beginning March 10, 2026, until the option is fully vested on February 9, 2029, subject to the Reporting Person's provision of service to…

  2. F2

    Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.

  3. F3

    The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2026, subject to the Reporting Person's provision of services to the…

  4. F4

    RSUs do not expire; they either vest or are canceled prior to the vest date.

Original filing · 0001817199-26-000008
Related transactions

0 other filings

Same reporting owner
Recent company activity

0 recent txs

NRIX